System and method to evaluate cardiovascular health
First Claim
Patent Images
1. A system to evaluate safety of a medication, comprising:
- an evaluation component adapted to measure a first cardiovascular marker associated with a circulatory system of a subject and a second cardiovascular marker associated with the circulatory system of the subject to determine a fluid retention value based at least in part upon the cardiovascular markers received, wherein the first cardiovascular marker is measured before the medication is administered to the subject and wherein the second cardiovascular marker is measured after the medication is administered, and wherein the first and second cardiovascular markers include at least one cardiovascular marker selected from the group consisting of stroke volume of the circulatory system of the subject, mass of blood per heart stroke of the subject, a volume of blood within the circulatory system of the subject, a plasma volume within the circulatory system of the subject, a turbulence of blood flow within the circulatory system of the subject, a velocity of blood flow within the circulatory system of the subject, a fluid retention measurement associated with the circulatory system of the subject, an intravascular volume of the circulatory system of the subject, a degree of leg edema of the subject, a body weight of the subject, a body mass of the subject, a nutriuretic peptide level of the subject, a blood pressure of the subject, a pressure at which the blood is ejected from the heart of the subject, a cardiac work of the subject, a cardiac output of the subject, viscosity of blood within the circulatory system of the subject, serum osmolality within the circulatory system of the subject, density of blood within the circulatory system of the subject, Reynolds number associated with the circulatory system of the subject;
a memory store adapted to store the first and second cardiovascular markers from the subject, the memory store also receives subject information selected from the group consisting of age, gender, heredity, blood pressure, serum cholesterol level, lipoprotein level, tobacco use, subject weight, a biomarker, and glucose intolerance;
wherein the evaluation component is in communication with the memory store and a reporting component, the evaluation component determines a fluid retention threshold based on at least the subject information, the evaluation component also evaluates the cardiovascular health of the subject by comparing the fluid retention value to the fluid retention threshold, and wherein if the fluid retention value is greater than the fluid retention threshold, the evaluation component provides an evaluation to the reporting component containing a recommendation to discontinue use of the medication;
wherein the first cardiovascular marker and second cardiovascular marker includes a calculation of a Reynolds number, wherein the evaluation component calculates the Reynolds number using at least one of cardiac output, intravascular volume, blood pressure, blood flow, mass of the blood, mass of the blood per stroke, density of the blood, volume of the blood, plasma volume, stroke volume, viscosity of the blood, serum osmolality, velocity of the blood, and turbulence of the blood of the subject.
0 Assignments
0 Petitions
Accused Products
Abstract
Systems and methods are described herein to evaluate a candidate medication as it relates to a subject'"'"'s cardiovascular health. A processing component is employed to measure a first value of one or more cardiovascular markers, via a computer, which are associated with a circulatory system of each subject that is to receive the candidate medication. The candidate medication is administered to each subject and a second value of one or more cardiovascular markers are measured subsequent to the administration as of the candidate medication. Continued testing of the candidate medication can be continued dependent upon the change in the one or more cardiovascular markers.
-
Citations
3 Claims
-
1. A system to evaluate safety of a medication, comprising:
-
an evaluation component adapted to measure a first cardiovascular marker associated with a circulatory system of a subject and a second cardiovascular marker associated with the circulatory system of the subject to determine a fluid retention value based at least in part upon the cardiovascular markers received, wherein the first cardiovascular marker is measured before the medication is administered to the subject and wherein the second cardiovascular marker is measured after the medication is administered, and wherein the first and second cardiovascular markers include at least one cardiovascular marker selected from the group consisting of stroke volume of the circulatory system of the subject, mass of blood per heart stroke of the subject, a volume of blood within the circulatory system of the subject, a plasma volume within the circulatory system of the subject, a turbulence of blood flow within the circulatory system of the subject, a velocity of blood flow within the circulatory system of the subject, a fluid retention measurement associated with the circulatory system of the subject, an intravascular volume of the circulatory system of the subject, a degree of leg edema of the subject, a body weight of the subject, a body mass of the subject, a nutriuretic peptide level of the subject, a blood pressure of the subject, a pressure at which the blood is ejected from the heart of the subject, a cardiac work of the subject, a cardiac output of the subject, viscosity of blood within the circulatory system of the subject, serum osmolality within the circulatory system of the subject, density of blood within the circulatory system of the subject, Reynolds number associated with the circulatory system of the subject; a memory store adapted to store the first and second cardiovascular markers from the subject, the memory store also receives subject information selected from the group consisting of age, gender, heredity, blood pressure, serum cholesterol level, lipoprotein level, tobacco use, subject weight, a biomarker, and glucose intolerance; wherein the evaluation component is in communication with the memory store and a reporting component, the evaluation component determines a fluid retention threshold based on at least the subject information, the evaluation component also evaluates the cardiovascular health of the subject by comparing the fluid retention value to the fluid retention threshold, and wherein if the fluid retention value is greater than the fluid retention threshold, the evaluation component provides an evaluation to the reporting component containing a recommendation to discontinue use of the medication; wherein the first cardiovascular marker and second cardiovascular marker includes a calculation of a Reynolds number, wherein the evaluation component calculates the Reynolds number using at least one of cardiac output, intravascular volume, blood pressure, blood flow, mass of the blood, mass of the blood per stroke, density of the blood, volume of the blood, plasma volume, stroke volume, viscosity of the blood, serum osmolality, velocity of the blood, and turbulence of the blood of the subject.
-
-
2. A system to evaluate safety of a medication, comprising:
-
an evaluation component adapted to measure a first cardiovascular marker associated with a circulatory system of a subject and a second cardiovascular marker associated with the circulatory system of the subject to determine a fluid retention value based at least in part upon the cardiovascular markers received, wherein the first cardiovascular marker is measured before the medication is administered to the subject and wherein the second cardiovascular marker is measured after the medication is administered, and wherein the first and second cardiovascular markers include at least one cardiovascular marker selected from the group consisting of stroke volume of the circulatory system of the subject, mass of blood per heart stroke of the subject, a volume of blood within the circulatory system of the subject, a plasma volume within the circulatory system of the subject, a turbulence of blood flow within the circulatory system of the subject, a velocity of blood flow within the circulatory system of the subject, a fluid retention measurement associated with the circulatory system of the subject, an intravascular volume of the circulate system of the subject, a degree of leg edema of the subject, a body weight of the subject, a body mass of the subject, a nutriuretic peptide level of the subject, a blood pressure of the subject, a pressure at which the blood is ejected from the heart of the subject, a cardiac work of the subject, a cardiac output of the subject, viscosity of blood within the circulatory system of the subject, serum osmolality within the circulatory system of the subject, density of blood within the circulatory system of the subject, Reynolds number associated with the circulatory system of the subject; a memory store adapted to store the first and second cardiovascular markers from the subject, the memory store also receives subject information selected from the group consisting of age, gender, heredity, blood pressure, serum cholesterol level, lipoprotein level, tobacco use, subject weight, a biomarker, and glucose intolerance; wherein the evaluation component is in communication with the memory store and a reporting component, the evaluation component determines a fluid retention threshold based on at least the subject information, the evaluation component also evaluates the cardiovascular health of the subject by comparing the fluid retention value to the fluid retention threshold, and wherein if the fluid retention value is greater than the fluid retention threshold, the evaluation component provides an evaluation to the reporting component containing a recommendation to discontinue use of the medication; wherein the evaluation component determines the difference between the fluid retention threshold and fluid retention value as a fluid retention percentage, and wherein the system further includes a medication selection component in communication with the evaluation component to receive the fluid retention percentage from the evaluation component, the medication selection component includes a first tier of 0-4%, a second tier of 5-9%, a third tier of 10-14% and a fourth tier of 15-20%, the medication selection component being adapted to recommend an alternative medication from a plurality of alternative medications based on the tier in which the fluid retention percentage falls and communicate the alternative medication recommendation to the reporting component. - View Dependent Claims (3)
-
Specification